MNMD missed EPS expectations by 35.90%
Mar 06, 2025, 11:33 PM
0.00%
What does MNMD do
Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company based in New York, focused on developing novel treatments for brain health disorders, including MM-120 for anxiety and ADHD, and MM-402 for autism. Founded in 2015, the company employs 57 people and targets neurotransmitter pathways using psychedelics and empathogens.
Mind Medicine (MNMD) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Mind Medicine's actual EPS was -$0.41, missing the estimate of -$0.30 per share, resulting in a -35.90% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.